Information Density: HEMLIBRA (Genentech) – Signal Evidence & AI Readability

[IMG: HEMLIBRA® (emicizumab-kxwh) Life Doesn]

[H3] Ian, on HEMLIBRA since 2020, son of HEMLIBRA Ambassador, Veronica
See More Stories

[H5] Every person's hemophilia A journey is different. Always talk to your healthcare provider before starting a new activity.

[IMG: HEMLIBRA® (emicizumab-kxwh) Logo Icon]

[H3] HEMLIBRA is the #1 prescribed prophylaxis for people with hemophilia A without factor VIII inhibitors*

*According to IQVIA claims data (various insurance plan types) from Jul’24-Jun’25 (Refreshed Sep’25), accounting for prophylaxis use in the US.

[IMG: HEMLIBRA® (emicizumab-kxwh) Ambassador Group Selfie]

[H3] Hear From the Community
9 in 10 people are highly satisfied with their HEMLIBRA treatment.†

Say Hello

[IMG: HEMLIBRA® (emicizumab-kxwh) Ambassador Miles]

[H3] Move on From Highs and Lows
HEMLIBRA's unique 4-week half-life offers consistent and sustained drug levels.

Learn More

[IMG: HEMLIBRA® (emicizumab-kxwh) Ambassador Maria and Carlos]

[H3] Support, Tips, and Tricks
Your guide to a more comfortable injection experience.

Get Tips

†Based on a blinded survey of 62 people with hemophilia A without inhibitors and their caregivers who were asked about current HEMLIBRA treatment and ranked their satisfaction on a scale of 1: Not at all satisfied to 7: Extremely satisfied. 55 respondents rated HEMLIBRA as 6 or 7. Commissioned by Genentech in September 2023.

HEMLIBRA (emicizumab-kxwh) is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.
With a half-life of four weeks, it provides consistent and sustained drug levels between doses and proven bleed protection as demonstrated by clinical trials.
HEMLIBRA acts like a bridge, bringing factor IXa and factor X together to help your blood clot. HEMLIBRA allows the blood coagulation process to continue without needing to replace factor VIII.
HEMLIBRA is administered as a subcutaneous injection given as a shot under the skin (a subcutaneous injection), so you don't need to find a vein to take your dose of HEMLIBRA. It can be taken at home after training from a healthcare provider. After four weeks of weekly loading doses, it offers flexible dosing options, including once weekly, every two weeks, or every four weeks.
People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots, conditions that require immediate medical attention. Common side effects include injection site reactions, headache, and joint pain.

[H3]
Important Safety Information & Indication

Back to Top

[H3] What is HEMLIBRA?
HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?
HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.
These serious side effects include:
Thrombotic microangiopathy (TMA), a condition involving blood clots and injury to small blood  vessels that may cause harm to your kidneys, brain, and other organs
Blood clots (thrombotic events), which may form in blood vessels in your arm, leg, lung, or head
Talk to your doctor about the signs and symptoms of these serious side effects, which can include:
Confusion
Stomach, chest, or back pain
Weakness
Nausea or vomiting
Swelling, pain, or redness
Feeling sick or faint
Decreased urination
Swelling of arms and legs
Yellowing of skin and eyes
Eye pain, swelling, or trouble seeing
Fast heart rate
Numbness in your face
Headache
Shortness of breath
Coughing up blood
If you experience any of these symptoms during or after treatment with HEMLIBRA, get medical help right away.
Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total.
Your body may make antibodies against HEMLIBRA, which may stop HEMLIBRA from working properly. Contact your healthcare provider immediately if you notice that HEMLIBRA has stopped working for you (eg, increase in bleeds).
The most common side effects of HEMLIBRA include: injection site reactions (redness, tenderness, warmth, or itching at the site of injection), headache, and joint pain. These are not all of the possible side effects of HEMLIBRA. You can speak with your healthcare provider for more information.
What else should I know about HEMLIBRA?
See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.
Stop taking your prophylactic bypassing therapy the day before you start HEMLIBRA
You may continue taking your prophylactic factor VIII for the first week of HEMLIBRA
HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and create an inaccurate result. Speak with your healthcare provider about how this may affect your care.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Only use HEMLIBRA for the condition it was prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them.
Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist.
Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.
Since HEMLIBRA was tested in males, there is no information on whether HEMLIBRA may impact your unborn baby or breast milk. Females who are able to become pregnant should use birth control during treatment.
Side effects may be reported to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see Important Safety Information, including Serious Side Effects, as well as the HEMLIBRA full Prescribing Information and Medication Guide.

[H1] What is HEMLIBRA?

[IMG: HEMLIBRA® (emicizumab-kxwh) Injecting HEMLIBRA Inject Icon Taking HEMLIBRA]

[H5] HEMLIBRA is the first subcutaneous injection for hemophilia A with or without inhibitors
HEMLIBRA is a medicine that is given as a shot that goes directly under the skin (a subcutaneous injection), so you don't need to find a vein to take your dose of HEMLIBRA.

[H2] Move on from highs and lows

Life has its ups and downs, but with HEMLIBRA, you can count on consistent and sustained drug levels and proven bleed protection between doses, demonstrated by our clinical trials.

[H5] Sail into steady waters with HEMLIBRA and its extended half-life
The term “half-life” in medicine means how long it takes for half the amount of a drug to leave the body. A longer half-life means the medicine stays in your body longer.

[IMG: HEMLIBRA® (emicizumab-kxwh) Roller Coaster Icon]

The half-life of factor VIII treatment is less than or equal to 48 hours.

[IMG: HEMLIBRA® (emicizumab-kxwh) Sailboat Icon]

The half-life of HEMLIBRA is ~4 weeks giving you consistent and sustained drug levels.

[H4] Average level of HEMLIBRA in your blood*

[IMG: Average level of HEMLIBRA® (emicizumab-kxwh) within patient bloodstream]

*For all 3 dosing groups, the levels of HEMLIBRA were within the therapeutic range. A therapeutic range is the range of drug levels that may be expected to achieve a therapeutic treatment effect.

[H2] While taking HEMLIBRA, it’s not necessary to monitor your drug levels

[H5] HEMLIBRA can be taken once a week, once every 2 weeks, or once every 4 weeks
For the first 4 weeks of treatment, you’ll use HEMLIBRA once a week. This will build up the levels of HEMLIBRA in your blood. After that, your doctor will help you choose a dosing schedule that’s right for you.
For more information on your HEMLIBRA dosing schedules, click here.

[IMG: HEMLIBRA® (emicizumab-kxwh) Ambassador Gabe]

[H5] “You could literally go from infusing yourself to injecting yourself just twice a month.”
— Gabe, takes HEMLIBRA for hemophilia A without factor inhibitors, Texas

Gabe takes HEMLIBRA every 2 weeks. When starting HEMLIBRA, a "loading dose" is taken once weekly for 4 weeks. After that, HEMLIBRA offers 3 regular dosing options: once weekly, once every 2 weeks, or once every 4 weeks. Talk to your doctor about dosing, or see the HEMLIBRA Medication Guide and Instructions for Use for full dosing and administration information.

[H2] Learn more about this family's journey with hemophilia

[H5] Sign Up for One-on-One Support
HEMLIBRA Account and Community Managers (ACMs) can provide support in both English and Spanish.

Get Support Resources

[H5] Chat Easily With Your Doctor
Use this handy discussion guide to get the most out of your conversation.

See the Guide

NEXT: How HEMLIBRA Works

[H3]
Important Safety Information & Indication

Back to Top

[H3] What is HEMLIBRA?
HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?
HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.
These serious side effects include:
Thrombotic microangiopathy (TMA), a condition involving blood clots and injury to small blood  vessels that may cause harm to your kidneys, brain, and other organs
Blood clots (thrombotic events), which may form in blood vessels in your arm, leg, lung, or head
Talk to your doctor about the signs and symptoms of these serious side effects, which can include:
Confusion
Stomach, chest, or back pain
Weakness
Nausea or vomiting
Swelling, pain, or redness
Feeling sick or faint
Decreased urination
Swelling of arms and legs
Yellowing of skin and eyes
Eye pain, swelling, or trouble seeing
Fast heart rate
Numbness in your face
Headache
Shortness of breath
Coughing up blood
If you experience any of these symptoms during or after treatment with HEMLIBRA, get medical help right away.
Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total.
Your body may make antibodies against HEMLIBRA, which may stop HEMLIBRA from working properly. Contact your healthcare provider immediately if you notice that HEMLIBRA has stopped working for you (eg, increase in bleeds).
The most common side effects of HEMLIBRA include: injection site reactions (redness, tenderness, warmth, or itching at the site of injection), headache, and joint pain. These are not all of the possible side effects of HEMLIBRA. You can speak with your healthcare provider for more information.
What else should I know about HEMLIBRA?
See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.
Stop taking your prophylactic bypassing therapy the day before you start HEMLIBRA
You may continue taking your prophylactic factor VIII for the first week of HEMLIBRA
HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and create an inaccurate result. Speak with your healthcare provider about how this may affect your care.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Only use HEMLIBRA for the condition it was prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them.
Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist.
Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.
Since HEMLIBRA was tested in males, there is no information on whether HEMLIBRA may impact your unborn baby or breast milk. Females who are able to become pregnant should use birth control during treatment.
Side effects may be reported to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see Important Safety Information, including Serious Side Effects, as well as the HEMLIBRA full Prescribing Information and Medication Guide.

[H1] Sign Up for HEMLIBRA and Hemophilia A Information and Support

[H1] Thanks for signing up!

[H2] We’re glad to provide you with resources
Thanks for joining. Be on the lookout for helpful emails from us soon. We look forward to being a resource for you to learn more about HEMLIBRA. If you have any immediate questions, please reach out to your local Account and Community Manager (ACM).
Learn More About Your ACM

NEXT: FAQs

[H3]
Important Safety Information & Indication

Back to Top

[H3] What is HEMLIBRA?
HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?
HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.
These serious side effects include:
Thrombotic microangiopathy (TMA), a condition involving blood clots and injury to small blood  vessels that may cause harm to your kidneys, brain, and other organs
Blood clots (thrombotic events), which may form in blood vessels in your arm, leg, lung, or head
Talk to your doctor about the signs and symptoms of these serious side effects, which can include:
Confusion
Stomach, chest, or back pain
Weakness
Nausea or vomiting
Swelling, pain, or redness
Feeling sick or faint
Decreased urination
Swelling of arms and legs
Yellowing of skin and eyes
Eye pain, swelling, or trouble seeing
Fast heart rate
Numbness in your face
Headache
Shortness of breath
Coughing up blood
If you experience any of these symptoms during or after treatment with HEMLIBRA, get medical help right away.
Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total.
Your body may make antibodies against HEMLIBRA, which may stop HEMLIBRA from working properly. Contact your healthcare provider immediately if you notice that HEMLIBRA has stopped working for you (eg, increase in bleeds).
The most common side effects of HEMLIBRA include: injection site reactions (redness, tenderness, warmth, or itching at the site of injection), headache, and joint pain. These are not all of the possible side effects of HEMLIBRA. You can speak with your healthcare provider for more information.
What else should I know about HEMLIBRA?
See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.
Stop taking your prophylactic bypassing therapy the day before you start HEMLIBRA
You may continue taking your prophylactic factor VIII for the first week of HEMLIBRA
HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and create an inaccurate result. Speak with your healthcare provider about how this may affect your care.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Only use HEMLIBRA for the condition it was prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them.
Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist.
Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.
Since HEMLIBRA was tested in males, there is no information on whether HEMLIBRA may impact your unborn baby or breast milk. Females who are able to become pregnant should use birth control during treatment.
Side effects may be reported to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see Important Safety Information, including Serious Side Effects, as well as the HEMLIBRA full Prescribing Information and Medication Guide.

[H1] Important Safety Information

[H3] What is HEMLIBRA?
HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?
HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.
These serious side effects include:
Thrombotic microangiopathy (TMA), a condition involving blood clots and injury to small blood  vessels that may cause harm to your kidneys, brain, and other organs
Blood clots (thrombotic events), which may form in blood vessels in your arm, leg, lung, or head
Talk to your doctor about the signs and symptoms of these serious side effects, which can include:
Confusion
Stomach, chest, or back pain
Weakness
Nausea or vomiting
Swelling, pain, or redness
Feeling sick or faint
Decreased urination
Swelling of arms and legs
Yellowing of skin and eyes
Eye pain, swelling, or trouble seeing
Fast heart rate
Numbness in your face
Headache
Shortness of breath
Coughing up blood
If you experience any of these symptoms during or after treatment with HEMLIBRA, get medical help right away.
Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total.
Your body may make antibodies against HEMLIBRA, which may stop HEMLIBRA from working properly. Contact your healthcare provider immediately if you notice that HEMLIBRA has stopped working for you (eg, increase in bleeds).
The most common side effects of HEMLIBRA include: injection site reactions (redness, tenderness, warmth, or itching at the site of injection), headache, and joint pain. These are not all of the possible side effects of HEMLIBRA. You can speak with your healthcare provider for more information.
What else should I know about HEMLIBRA?
See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.
Stop taking your prophylactic bypassing therapy the day before you start HEMLIBRA
You may continue taking your prophylactic factor VIII for the first week of HEMLIBRA
HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and create an inaccurate result. Speak with your healthcare provider about how this may affect your care.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Only use HEMLIBRA for the condition it was prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them.
Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist.
Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.
Since HEMLIBRA was tested in males, there is no information on whether HEMLIBRA may impact your unborn baby or breast milk. Females who are able to become pregnant should use birth control during treatment.
Side effects may be reported to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see Important Safety Information, including Serious Side Effects, as well as the HEMLIBRA full Prescribing Information and Medication Guide.